Core Viewpoint - MetaVia Inc. has successfully closed an underwritten public offering, raising approximately $9.3 million for the development of its cardiometabolic disease treatments [1][3]. Group 1: Offering Details - The public offering included 3,005,574 shares of common stock and 9,016,722 warrants (4,508,361 Series C Warrants and 4,508,361 Series D Warrants) at a price of $3.10 per share [2]. - The Series C and Series D Warrants are immediately exercisable at an exercise price of $3.10, with Series C expiring in five years and Series D in two years [2]. - The Series D Warrants can be called by the company following a positive data readout from its Phase 1b Part III clinical trial for DA-1726 [2]. Group 2: Financial Implications - If fully exercised, the warrants could yield up to approximately $28.0 million in future gross proceeds [3]. - The net proceeds from the offering will be used for working capital and general corporate purposes, specifically to continue the clinical development of DA-1726 for obesity treatment [3]. Group 3: Company Overview - MetaVia Inc. is focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [7]. - DA-1726 is a novel oxyntomodulin analogue that acts as a dual agonist for GLP1R and GCGR, showing potential for superior weight loss and glucose control [7]. - Vanoglipel (DA-1241) is a GPR119 agonist that has shown positive effects on liver inflammation and glucose metabolism in pre-clinical studies [7].

Core Viewpoint - Intelligent Bio Solutions Inc. has entered into a securities purchase agreement to raise approximately $10 million through a private placement of common stock and warrants, aimed at enhancing its working capital and general corporate purposes [1][2]. Group 1: Securities Offering - The company will issue 2,298,850 shares of common stock and associated Series K-1 and K-2 warrants, priced at $4.35 per share, with expected gross proceeds of around $10 million before expenses [1]. - The Series K-1 and K-2 warrants will have an exercise price of $4.10 per share and will be exercisable immediately upon issuance, with a term of five years [1]. - The closing of the private placement is anticipated on or about January 2, 2026, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the private placement will be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - Intelligent Bio Solutions Inc. specializes in medical technology, focusing on intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [5]. - The company's technology allows for quick sample collection and results in under ten minutes, targeting industries such as construction, manufacturing, and transport [5].

Core Viewpoint - Akari Therapeutics has announced a definitive agreement for the issuance and sale of approximately 12.6 million American Depositary Shares (ADSs) and unregistered warrants, with significant participation from its Directors, Officers, and Executive Management, aimed at supporting its oncology drug development initiatives and improving its capital structure [1][4][6]. Group 1: Offering Details - The offering includes 10,043,774 ADSs in a registered direct offering priced at $0.3883 per ADS, along with unregistered Series G warrants [3]. - A concurrent private placement will issue unregistered pre-funded warrants for 2,563,713 ADSs at a combined price of $0.4041 per ADS [3]. - The gross proceeds from the offering are expected to be around $5 million, with over $1 million coming from new cash investments by the Company's Directors, Officers, and Executive Management [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for ongoing research and development, working capital, and general corporate purposes [4]. Group 3: Debt Conversion - Existing note holders have agreed to convert approximately $2.5 million of the Company's outstanding debt into unregistered pre-funded warrants and warrants to purchase 6,409,410 ADSs at a combined exchange price of $0.4041 per ADS [5]. Group 4: Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs), with its lead candidate AKTX-101 targeting the Trop2 receptor on cancer cells [10]. - The novel payload PH1 is designed to disrupt RNA splicing within cancer cells, showing significant activity and prolonged survival in preclinical studies compared to traditional ADCs [10].

As filed with the Securities and Exchange Commission on December 1, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jet.AI Inc. (Exact name of registrant as specified in its charter.) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Number) Delaware 4522 93-2971741 (IRS Employer Identification No.) 10845 Griffith Peak Dr. Suite 200 Las ...

Core Points - Salarius Pharmaceuticals Inc. shares increased by 23.65% in after-hours trading, closing at $1.21, following the announcement of pricing details for its public offering [1] - The stock had previously dropped 51% during regular trading, closing at $0.98 [1] Offering Details - Salarius announced a public offering aimed at raising approximately $7 million in gross proceeds before fees [2] - The offering includes 2.51 million common stock shares and pre-funded warrants for 2.15 million shares, priced at $1.50 per share [2] Warrant Structure and Terms - The exercise price for both Series A and Series B warrants is set at $1.50 [3] - Series B warrants have a one-year exercise window, while Series A warrants can be exercised for five years after issuance [3] - The warrants feature fixed pricing with no variable pricing elements [3] Merger-Contingent Closing - The closing of the offering is contingent upon the completion of Salarius' proposed business combination with Decoy Therapeutics Inc., expected to occur on Wednesday [4] - Ladenburg Thalmann & Co. Inc. is the sole book-running manager for the offering [4] - Proceeds from the offering will be used to fund research programs, repay Decoy's promissory notes, and cover working capital needs [4] Stock Performance - Year-to-date, Salarius' stock has decreased by 96.25% [5] - The company has a market capitalization of $1.03 million and an average daily trading volume of 318,090 shares [5] - Benzinga Edge Stock Rankings indicate a negative price trend for SLRX across all time frames [5]

Core Viewpoint - STRATA Skin Sciences, Inc. has announced a registered direct offering of 1,097,547 shares of common stock at a price of $2.204 per share, aiming to raise approximately $2.42 million for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The offering is being facilitated by Ladenburg Thalmann & Co. Inc. as the exclusive placement agent, with the closing expected around September 4, 2025, pending customary closing conditions [2]. - The gross proceeds from the offering, before deducting fees and expenses, are projected to be about $2.42 million [3]. Group 2: Company Overview - STRATA Skin Sciences is focused on developing and marketing innovative products for dermatologic conditions, including psoriasis, vitiligo, and acne, with products like the XTRAC excimer laser and TheraClearX Acne Therapy System [6]. - The company employs a unique Partnership Program that offers a fee per treatment cost structure, providing on-site training, service, maintenance, and advertising support to practices [7].

Core Viewpoint - Calidi Biotherapeutics, Inc. has successfully closed a public offering, raising gross proceeds of $6.9 million, which includes the full exercise of the underwriters' over-allotment option [1][2]. Group 1: Offering Details - The company sold a total of 1,922,764 common stock units, each consisting of one share of common stock and one Series I warrant, and 1,528,000 pre-funded warrant units, each consisting of one pre-funded warrant and one Series I warrant [2]. - The price per Common Stock Unit was set at $2.00, while the Pre-Funded Unit was priced at $1.999 [2]. - The Series I warrants have an exercise price of $2.00 per share, are exercisable upon issuance, and will expire five years from issuance [2]. Group 2: Management and Regulatory Information - Ladenburg Thalmann & Co. Inc. served as the sole book-running manager for the offering, with Laidlaw & Company (U.K.) Ltd. acting as a co-manager [3]. - The securities were offered under a registration statement on Form S-1, which was declared effective by the SEC on August 20, 2025 [4]. Group 3: Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted therapies that can deliver genetic medicines to distal disease sites [6]. - The company's proprietary Redtail platform utilizes an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites, aiming to enhance the effectiveness of virotherapy [6]. - The lead candidate from the Redtail platform is currently in IND-enabling studies and targets non-small cell lung cancer, ovarian cancer, and other tumor types with significant unmet medical needs [7].

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments [2][3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which aims to detect and differentiate neural signals with greater sensitivity than current technologies [3][4] Technology and Applications - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [4] Upcoming Events - The President and CEO of Autonomix, Brad Hauser, will participate in a virtual investor webinar hosted by Ladenburg Thalmann on August 21, 2025, at 1:00 PM ET [2][3] - The webinar will include a question and answer session, allowing participants to pre-submit questions [3]

Core Viewpoint - Fractyl Health, Inc. has announced a public offering of 19,047,619 shares of common stock, along with Tranche A and Tranche B warrants, aiming for gross proceeds of $20 million to support its metabolic disease treatment programs [1][5]. Offering Details - The shares are priced at $1.05 each, with each share sold together with one Tranche A warrant (2-year term) and one Tranche B warrant (5-year term) [2]. - The exercise price for both warrant tranches is set at $1.05 per share, and the warrants do not have variable priced resetting mechanisms or price-based anti-dilution features [2]. - The Tranche A warrants can be called by the company after the release of 3-month randomized midpoint clinical data from the ongoing REMAIN-1 study, contingent on certain conditions being met [3]. Additional Options - The underwriters have a 30-day option to purchase up to an additional 2,857,142 shares of common stock, along with associated warrants, at the public offering price [4]. Financial Projections - The company expects to receive approximately $20 million from this offering, with potential future proceeds of up to $40 million if the warrants are fully exercised for cash [5]. - The net proceeds will be utilized to support the Revita and Rejuva pipeline programs, as well as for working capital and other general corporate purposes [5]. Company Background - Fractyl is focused on innovative treatments for metabolic diseases, including obesity and type 2 diabetes, aiming to shift from chronic symptomatic management to durable disease-modifying therapies [9]. - The company holds a robust intellectual property portfolio, with 32 granted U.S. patents and around 40 pending U.S. applications, alongside numerous foreign patents [9].

Core Viewpoint - Fractyl Health, Inc. is planning to conduct an underwritten public offering of its common stock and pre-funded warrants to raise capital for its pipeline programs and general corporate purposes [1][2]. Group 1: Offering Details - The company intends to sell shares of its common stock and pre-funded warrants, with each pre-funded warrant priced slightly lower than the common stock price [1]. - Fractyl expects to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the final terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to support the Revita and Rejuva pipeline programs, along with working capital and other general corporate purposes [2]. Group 3: Company Overview - Fractyl Health focuses on innovative treatments for metabolic diseases, particularly obesity and type 2 diabetes, aiming to shift from chronic management to disease-modifying therapies [5]. - The company holds a robust intellectual property portfolio, including 32 granted U.S. patents and approximately 40 pending applications [5]. - Fractyl is headquartered in Burlington, Massachusetts, and aims to redefine metabolic disease treatment [5].